Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROSTAT vs IMDUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute relief of angina pectoris,Prophylaxis of angina pectoris before activities that may provoke an attack,Off-label: Treatment of acute heart failure, hypertensive urgency
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
2–3 minutes for initial distribution phase; terminal elimination half-life is approximately 1–4 minutes. Rapid clearance due to extensive metabolism in the liver and other tissues (via glutathione-organic nitrate reductase).
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Rapidly metabolized in the liver by glutathione-organic nitrate reductase and by erythrocytes; CYP450 not primarily involved.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Renal excretion of inactive metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for about 35%. Unchanged nitroglycerin is minimally excreted in urine (<1%).
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Approximately 60% bound to plasma proteins (albumin and possibly others).
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
3–4 L/kg, indicating extensive distribution into tissues, particularly vascular smooth muscle and other highly perfused organs.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Sublingual: 30–60% (bypasses first-pass hepatic metabolism). Oral: <10% due to extensive first-pass metabolism. Transdermal: 10–20% depending on formulation and application site. Intravenous: 100%.
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
No dosage adjustment required for renal impairment; use with caution in patients with severe renal impairment due to potential for hypotension.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Caution, consider dose reduction; Child-Pugh Class C: Avoid use due to increased risk of methemoglobinemia.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
Not recommended for use in children due to lack of safety and efficacy data.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Initiate at lower end of dosing range (0.3 mg) due to increased sensitivity to vasodilation and higher risk of hypotension; monitor closely.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) as this can cause severe hypotension, syncope, or myocardial ischemia.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
Hypotension and reflex tachycardia may occur,May exacerbate angina due to excessive hypotension,Tolerance may develop with prolonged use,Abrupt discontinuation may precipitate angina
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypersensitivity to nitroglycerin,Concurrent use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe hypotension (systolic BP <90 mm Hg),Cardiac tamponade, constrictive pericarditis, or restrictive cardiomyopathy,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage)
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
Avoid alcohol, which can enhance hypotensive effects and cause severe dizziness or fainting. Grapefruit juice may increase nitroglycerin absorption and risk of adverse effects. No other significant food interactions.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
FDA Pregnancy Category C. Nitroglycerin crosses the placenta. Animal studies show no teratogenic effects. Use in first trimester only if clearly needed; second/third trimester: risk of fetal bradycardia and hypotension. Avoid near term due to potential for maternal hypotension and reduced uterine blood flow.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
Nitroglycerin is excreted into breast milk in small amounts; M/P ratio unknown. No known adverse effects in infants. Use with caution, especially in nursing of premature or ill infants.
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
No specific dose adjustment required for pregnancy; however, due to increased plasma volume and altered hemodynamics, monitor efficacy and titrate to response. Use lowest effective dose to minimize maternal hypotension.
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
Nitroglycerin sublingual tablets (Nitrostat) are first-line for acute angina. Store in original glass bottle, tightly closed; potency degrades with exposure to light, heat, and moisture. Patients should feel a tingling or burning sensation under the tongue—if absent, tablet may be ineffective. Administer 0.3-0.6 mg at first sign of angina; may repeat every 5 minutes up to 3 doses. If pain persists after 3 doses, seek emergency care. Contraindicated with recent use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Hypotension and reflex tachycardia are common; monitor blood pressure. Tolerance develops with sustained use; use minimal effective dose and allow nitrate-free interval (10-12 hours daily) for long-acting forms.
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Take at the first sign of chest pain; do not wait for severe pain.,Place the tablet under the tongue or between the cheek and gum; do not swallow or chew.,Sit or lie down when taking to avoid dizziness or fainting from low blood pressure.,If no relief after 5 minutes, repeat one dose; if still no relief after 3 doses in 15 minutes, call 911 immediately.,Store in the original glass bottle, tightly closed, away from heat and light; do not store in bathroom or kitchen.,Replace the bottle 6 months after opening, as the medication loses potency.,Do not drink alcohol while taking this medication; it can cause severe hypotension.,Do not take with erectile dysfunction drugs (Viagra, Cialis, Levitra) as it can cause a fatal drop in blood pressure.,Avoid grapefruit juice as it may increase side effects.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROSTAT vs IMDUR, answered by our medical review team.
NITROSTAT is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.. IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROSTAT and IMDUR depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROSTAT is: 0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.. The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROSTAT and IMDUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROSTAT is classified as Category C. FDA Pregnancy Category C. Nitroglycerin crosses the placenta. Animal studies show no teratogenic effects. Use in first trimester only if clearly needed; second/third trimester: ris. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.